High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children.

Objective. To determine the primary and secondary resistance to several antimicrobial agents in Spanish Helico - bacter pylori clinical isolates obtained from paediatric patients from January 2002 to June 2006. Methods. Samples were collected from gastric biopsies of symptomatic paediatric patients...

Descripción completa

Detalles Bibliográficos
Publicado en:Revista Española de Quimioterapia Vol. 22; no. 2; pp. 88 - 93
Autores principales: Agudo, S., Alarcón, T., Cibrelus, L., Urruzuno, P., Martínez, M. J., López-Brea, M.
Formato: Artículo
Publicado: Sociedad Espanola de Quimioterapia 2009
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=48548641&site=ehost-live
header:
  @attributes:
    shortDbName: lth
    uiTerm: 48548641
    longDbName: MedicLatina
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        02143429
        56RF
      jtl: Revista Española de Quimioterapia
      issn: 02143429
      maglogo: N
    pubinfo:
      dt: 2009
      vid: 22
      iid: 2
      pid: 41363
      pub: Sociedad Espanola de Quimioterapia
    artinfo:
      ui: 48548641
      ppf: 88
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
            size: 110KB
      tig:
        atl: High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children.
      aug:
        au:
          Agudo, S.
          Alarcón, T.
          Cibrelus, L.
          Urruzuno, P.
          Martínez, M. J.
          López-Brea, M.
        affil:
          Hospital de La Princesa Madrid (Spain)
          Hospital Universitario Doce de Octubre Madrid (Spain)
          Hospital Infantil Universitario Niño Jesús Madrid (Spain)
      su:
        Metronidazole
        Antibiotics
        Anti-infective agents
        Amoxicillin
        Ciprofloxacin
        Rifampin
        Pediatrics
      sug:
        subj:
          Metronidazole
          Antibiotics
          Anti-infective agents
          Amoxicillin
          Ciprofloxacin
          Rifampin
          Pediatrics
      keyword:
        Paediatrics
        Primary resistance
        Rifampicin
        Treatment failure
        Ciprofloxacino
        Pediátricos
        Resistencia primaria
        Rifampicina
        Tratamiento fracasado
      ab:
        Objective. To determine the primary and secondary resistance to several antimicrobial agents in Spanish Helico - bacter pylori clinical isolates obtained from paediatric patients from January 2002 to June 2006. Methods. Samples were collected from gastric biopsies of symptomatic paediatric patients and H. pylori cultured according to standard microbiological procedures. Resistance was determined by E-test. Strains were considered resistant if minimal inhibitory concentration (MIC) ⩾ 2 mg/l for amoxycillin, ⩾ 4 mg/l for tetracycline, ⩾ 8 mg/l for metronidazole, ⩾ 1 mg/l for clarithromycin, MIC ⩾ 4 mg/l for ciprofloxacin, MIC ⩾ 32 mg/l for rifampicin and intermediate if MIC = 0.5 mg/l for clarithromycin, and MIC = 2 mg/l for ciprofloxacin. Results. A total of 101 patients were included: 38 males and 63 females (sex ratio M/F: 0.6). Average age was 10 years (range: 4-18 years). All strains were susceptible to amoxycillin, tetracycline and rifampicin, 35.7% were resistant to metronidazole, 54.6% to clarithromycin and 1.8% to ciprofloxacin. 2.0% were intermediate to clarithromycin and 1.8% to ciprofloxacin. Double resistance to metronidazole and clarithromycin rated at 17.2%. Thirty-five patients (34.7%) had a history of treatment failure, and were considered as secondary H. pylori. Primary resistance rates to metronidazole and clarithromycin were 32.8% and 49.2%, respectively, and secondary resistance rates were 41.2% and 70.6%, respectively. Conclusions. Resistance to clarithromycin (56.6%) was higher than to metronidazole (35.7%) in the H. pylori strains studied. Clarithromycin resistance was very high even in strains from paediatric patients not previously treated for H. pylori infection.
        Introducción. Determinar la resistencia primaria y secundaria a varios agentes antibióticos en aislamientos clínicos de Helicobacter pylori procedentes de pacientes pediátricos desde enero de 2002 a junio de 2006. Métodos. Las muestras fueron biopsias gástricas procedentes de pacientes pediátricos sintomáticos. H. pylori fue cultivado acorde con los estándares de los procedimientos microbiológicos. La resistencia a antibióticos fue determinada mediante E-test. Los aislamientos fueron considerados resistentes si la CMI ⩾ 2 mg/l para amoxicilina, ⩾ 4 mg/l para tetraciclina, ⩾ 8 mg/l para metronidazol, ⩾ 1 mg/l para claritromicina, ⩾ 4 mg/l para ciprofloxacino y ⩾32 mg/l para rifampicina, y fue considerado intermedio si la concentración mínima inhibitoria (CMI) = 0,5 mg/l para claritromicina, y CMI = 2 mg/l para ciprofloxacino. Resultados. De los 101 pacientes incluidos en el estudio: 38 fueron hombres y 63 mujeres. La media de edad fue de 10 años. Todas las cepas fueron sensibles a amoxicilina, tetraciclina y rifampicina. El 35,7% de los aislamientos fueron resistentes a metronidazol, el 54,6% fueron resistentes a claritromicina y el 1,8% a ciprofloxacino. El 17,2% de los aislamientos tuvieron doble resistencia a metronidazol y claritromicina. Treinta y cinco pacientes (34,7%) tuvieron un fallo en el tratamiento frente a H. pylori, previamente. La resistencia primaria a metronidazol y claritromicina fue del 32,8 y 49,2%, respectivamente, y la resistencia secundaria fue de un 41,2 y 70,6%, respectivamente. Conclusión. La resistencia a claritromicina (56,6%) fue más alta que a metronidazol (35,7%) en los aislamientos clínicos de H. pylori estudiados. La resistencia a claritromicina fue alta incluso en los pacientes que no habían tenido tratamientos previos frente a H. pylori.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: Y
      custom: Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use.
      item: Revista Española de Quimioterapia
      holder: Sociedad Espanola de Quimioterapia
      dt:
        @attributes:
          year: 2009
    holdings:
      @attributes:
        islocal: N